Standard BioTools Reports Q1 Net Income of $127.1M Driven by Divestiture Gain; Faces Nasdaq Delisting Notice

summarizeSummary

Standard BioTools reported Q1 2026 net income of $127.1 million and a strong cash position of $526.5 million, largely due to the SomaScan business divestiture. However, the company also disclosed a Nasdaq delisting notice for its stock falling below the minimum bid price.

check_boxKey Events

• Strong Q1 Net Income Driven by Divestiture

  Standard BioTools reported a net income of $127.1 million ($0.33 EPS) for Q1 2026, a significant turnaround from a $26.0 million loss in Q1 2025. This was primarily due to a $172.3 million pre-tax gain from the sale of its SomaScan Business to Illumina, which closed on January 30, 2026.

• Substantial Increase in Cash and Investments

  The company's cash, cash equivalents, and investments increased to $526.5 million as of March 31, 2026, up from $213.3 million at December 31, 2025, largely from the SomaScan divestiture proceeds.

• Nasdaq Minimum Bid Price Deficiency Notice

  Standard BioTools received a notice from Nasdaq on April 20, 2026, indicating non-compliance with the minimum $1.00 bid price requirement. The company has until October 19, 2026, to regain compliance.

• Reduced Operating Expenses for Continuing Operations

  Operating expenses for continuing operations decreased by 37% year-over-year, with R&D down 61% and SG&A down 38%, reflecting the impact of prior restructuring activities and workforce reductions.

auto_awesomeAnalysis

Standard BioTools reported a significant net income of $127.1 million for Q1 2026, a substantial improvement from a $26.0 million loss in Q1 2025. This positive swing was primarily driven by a $172.3 million pre-tax gain from the sale of its SomaScan Business to Illumina, which closed on January 30, 2026. The company's cash, cash equivalents, and investments surged to $526.5 million as of March 31, 2026, up from $213.3 million at year-end 2025, providing a strong liquidity position. Operating expenses for continuing operations saw significant reductions, with R&D down 61% and SG&A down 38%, reflecting prior restructuring efforts. However, the company's continuing operations still reported a loss of $14.6 million and net cash used in operating activities increased to $46.6 million, indicating ongoing operational challenges. Critically, the company disclosed receiving a Nasdaq notice on April 20, 2026, for failing to meet the minimum $1.00 bid price requirement, with a compliance deadline of October 19, 2026. This delisting risk is a major concern for investors, overshadowing some of the financial improvements from the divestiture.